Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients Abstract: A large number of prostate cancer (PCa) patients receive treatment without significant benefits, strengthening the need for accurate prognosis, which can be supported by the study of miRNAs. In silico specific ity analysis was performed for the identification of miR NAs able to regulate KLK2 and KLK4 expression. Total RNA was extracted from prostate tissues obtained from PCa and benign prostate hyperplasia patients. There after, RNA was polyadenylated and reverse transcribed to cDNA, which was used for qPCR analysis. miR378 was predicted to target both KLK2 and KLK4 and down regulated levels detected in PCa patients (p = 0.050). The reduction of miR378 was correlated with higher Gleason score (p = 0.018), larger diameter tumors (p = 0.034), and elevated serum PSA (p = 0.006). Regarding prognosis, miR378 was able to improve risk stratification accord ing to Gleason score or tumor stage, while higher risk to recur highlighted for the patients expressing lower miR378 levels. Finally, the loss of miR378 was able to predict the shortterm relapse of 'high' and 'very high' recurrencerisk patients, independent of Gleason score, tumor stage, PSA, and age as indicated by KaplanMeier survival curves (p = 0.030) and multivariate Cox regres sion analysis (p = 0.018). In conclusion, loss of miR378 expression increases the risk for PCa progression and relapse, despite active treatment.
Introduction
Despite the ongoing debate about the reduction of pros tate cancer (PCa) mortality, the introduction of prostate specific antigen (PSA) screening of the male population is primarily responsible for the high rate of PCa diagnosis in Western populations. However, this beneficial use of PSA, as kallikreinrelated peptidase 3 (KLK3) is largely known, suffers from a high rate of overdiagnosis and overtreat ment (Andriole et al., 2009; Schroder et al., 2009) .
PCa is characterized by great heterogeneity in terms of disease progression rate and lifethreatening potential. Prostate tumors range from clinically insignificant and not life threatening to rapidly progressive and lethal ones, despite active treatment. Consequently, a large number of patients receive radical therapy without important clinical benefits, which further worsens healthrelated quality of life. Risk stratification and treatment decisions are mainly determined by Gleason score, pathological stage, serum PSA levels, and patient's life expectancy (Freedland, 2011) . However, the diverse outcomes of the same risk group of patients clearly highlight the need for a more accurate risk stratification and prognosis of the diagnosed patients, as well as more personalized patient's management.
KLK2 and KLK4 are two highly expressed members of the kallikreinrelated peptidases (KLK) gene family in the prostate gland, encoding for KLK2 and KLK4secreted serine proteases, both responsible for semen liquefaction (Borgono et al., 2004) . KLK2 and KLK4 are significantly overexpressed in PCa compared to benign or normal epi thelium (Darson et al., 1997; Herrala et al., 2001; Klokk et al., 2007; Avgeris et al., 2011) , facilitating prostate tum origenesis and cancer cells spread. KLK2 and KLK4 were able to deliver tumorigenic stimuli in prostate cells by the overactivation of the insulinlike growth factor (IGF) axis, through IGFbinding protein (IGFBP) degradation, the proteolytic cleavage of cell surface proteinaseactivated receptors 1 and 2 (PAR1 and 2) and the stimulation of AR and mTOR signaling in PCa cells. Moreover, the KLK2 and KLK4mediated cleavage of extracellular matrix (ECM) components facilitates cancer cell invasiveness and bone metastasis (Avgeris et al., 2010 (Avgeris et al., , 2012 Mavridis and Scorilas, 2010) . Therefore, the regulation of KLK2 and KLK4 expression is critical for prostate homeostasis and the progression of prostate malignancy.
Although the direct ARmediated regulation of KLK transcription in prostate gland is well documented, and several androgen response elements (AREs) have been identified in the promoter regions of KLK2 and KLK4 (Lawrence et al., 2010) , recent findings have drawn atten tion to miRNAs as a novel posttranscriptional regulators of KLK expression (Chow et al., 2008; Pasic et al., 2012) . Taking into account the deregulated levels of several miRNAs in PCa (Porkka et al., 2007; Schaefer et al., 2010a; Wach et al., 2012) , the identification of miRNAs targeting KLK2 and KLK4 and the evaluation of their clinical signifi cance for the patients would further support the need for improvement of disease prognosis.
In the present study, in an effort to improve the risk stratification of the PCa patients and the prediction accu racy of their survival outcome following treatment, we have identified, in silico, hsamiRNA3783p (miR378) as a common regulator of KLK2 and KLK4 expression, and thereafter, we analyzed its expression levels in PCa.
Results

miR-378-3p predicted to target KLK2 and KLK4 expression
Several miRNAs were predicted to bind on the 3′UTR of KLK2 and KLK4 mRNAs and, thus, to regulate their levels. In order to achieve a good balance between sen sitivity and specificity, we focused on those miRNAs pre dicted to target KLK2 and KLK4 by multiple programs. The miRNAs predicted to regulate both KLK2 and KLK4 by three or more programs are presented in Table 1 . As shown in Table 1 , hsamiR3783p and hsamiR422a, a paralog of hsamiR3783p, are the most probable candi dates to target both KLK2 and KLK4. The several variants of hsamiR3783p (miR378aj and miR422a), although they are encoded by different stemloop precursors, share the same seed sequence and, therefore, mRNA targets. Among them, hsamiR378a3p, previously annotated as hsamiR422b, is the predominantly expressed variant of the miR378/422a family. Taking into consideration the increased transcriptional levels of KLK2 and KLK4 and the reduced miR378 levels in prostate malignancy (Martens Uzunova et al., 2012) , we decided to investigate miR378 clinical significance for PCa patients.
Expression analysis of miR-378 in prostate tumors
Decreased miR378 levels (p = 0.050; Supplemental Figure 1 
Downregulation of miR-378 correlates with tumors of higher Gleason score and larger diameter as well as elevated serum PSA levels
In order to evaluate the prognostic significance of miR378 for PCa, the miR378 expression levels were analyzed relatively to the classical and clinically used prognostic markers. A statistically significant (p = 0.018) downregu lation of miR378 was observed as the disease progressed to poorly differentiated tumors ( Figure 1A ). More pre cisely, significantly lower miR378 levels were found in Gleason score ≥ 8 (median: 1.20 RQ units) and Gleason score 7 (median: 2.11 RQ units) tumors compared to those of Gleason score ≤ 6 (median: 4.37 RQ units). Addition ally, the reduction of miR378 in PCa was found to cor relate with higher PSA serum levels as significantly lower (p = 0.006) miR378 expression was detected in PSA ≥ 10 μg/l cohort (median: 1.34 RQ units) compared to 4-10 μg/l (median: 4.08 RQ units) and < 4 μg/l (median: 11.06 RQ units) cohorts ( Figure 1B ). This negative correla tion between miR378 and PSA levels was also supported by Spearman's correlation coefficient (r s : 0.273; p = 0.021; Figure 1C ). Finally, miR378 expression was also found to correlate with larger tumor diameter in PCa patients, as illustrated by Spearman's correlation (r s : 0.402; p = 0.034; Figure 1D ). However, no statistically significant correla tion was observed between miR378 levels and tumor stage (Supplemental Figure 2) . 
Downregulation of miR-378 highlights the poor disease-free survival of the patients and improves risk stratification
The prognostic significance of miR378 for patients' outcome following radical prostatectomy was assessed by KaplanMeier survival curves ( Figure 2A ) and Cox regres sion analysis (Table 2) . Although not statistically signifi cant, KaplanMeier curves (p = 0.070) and univariate Cox analysis (HR: 1.911; 95% CI: 0.932-3.921; p = 0.077) showed the unfavorable diseasefree survival (DFS) and the higher risk for biochemical relapse of the miR378() PCa patients compared to the miR378(+) ones.
In order to improve patients' risk stratification, the prognostic significance of miR378 was further analyzed in combination with patients' Gleason score and tumor stage. As indicated by KaplanMeier DFS curves, a more accurate prediction of the DFS expectancy following radical prostatectomy was achieved for the patients of the same Gleason score or tumor stage cohorts. More precisely, grouping patients according to Gleason score, miR378 loss was able to distinguish the patients with worse DFS outcome for both ≤ 3+4 and ≥ 4+3 groups ( Figure 2B ). Similarly, miR378 loss was demonstrated to predict the poor DFS for both ≤ pT2c and ≥ pT3a groups compared to patients with miR378 overexpression of the same cohorts ( Figure 2C ).
These findings clearly underscore the unfavorable outcome of the patients with reduced miR378 levels at the time of treatment and the beneficial impact of miR378 on the improvement of patients' risk stratification. Addition ally, the ability of miR378 loss to distinguish the patients with worse DFS outcome in the same Gleason score or tumor stage cohorts prompted us to study miR378 prog nostic significance in each individual recurrence risk groups. 
Loss of miR-378 predicts the short-term relapse of the high-recurrence risk patients
NCCN guidelines for PCa were used for the classification of the patients according to their recurrence risk (Mohler et al., 2010) . KaplanMeier analysis, as well as Cox regres sion analysis (Table 3) , was conducted in order to study miR378a prognostic value for each cohort.
Regarding 'high' and 'very high'recurrence risk patients ( ≥ pT3a or Gleason score 8-10 or PSA > 20 μg/l; Supplemental Table 1 ), a significantly (p = 0.030) higher risk for shortterm relapse was observed in the patients with reduced miR378 levels ( Figure 3A) . In particular, a significantly shorter DFS expectancy was demonstrated for the miR378() high and very highrisk patients compared to the miR378(+) ones. For the same group of patients, riskgroup stratification was not efficient enough to predict the DFS of the treated patients (p = 0.275; Figure 3B ), strengthening, in this way, the prognostic potential of miR378. Studying miR378 levels in low and intermediaterecurrence risk patients (Supplemental Table 1 ), similar DFS intervals were demonstrated for miR 378() and miR378(+) patients.
The significance of the miR378 expression in the prog nosis of 'high' and 'very high'recurrence risk patients was also supported by Cox regression survival analysis. A significantly higher risk to relapse (HR: 2.824; 95% CI: 1.051-7.585; p = 0.040) was observed in the miR378() patients compared to miR378(+) patients by univariate models. For the same patients' group, only Gleason score was proved to have a statistically significant prognostic value for the prediction of biochemical relapse. Finally, multivariate Cox regression models revealed prognos tic value of miR378 levels for the prediction of patients' DFS following treatment (HR: 4.792; 95% CI: 1.130-17.522; p = 0.018) independent from Gleason score, tumor stage, PSA, DRE, and age. Summarizing, miR378 loss in PCa represents an independent prognostic marker for the pre diction of high and very highrecurrence risk patients' shortterm relapse.
Discussion
Since their discovery, miRNAs have emerged as pow erful posttranscriptional gene expression regulatory mediators (Bartel, 2004) , and deregulated miRNA levels have been documented in the majority of human malig nancies (Calin and Croce, 2006; Bartels and Tsongalis, 2009 cancerrelated molecular cascades would aid to the elu cidation of the clinical significance for PCa patients' man agement (Schaefer et al., 2010b; Fendler et al., 2011; Larne et al., 2013; Lichner et al., 2013) . Using miRNAtarget prediction programs, miR3783p was found to be the most frequently predicted miRNA candidate able to regulate both KLK2 and KLK4 expres sion. This is in agreement with miRNA microarraybased results showing downregulated miR378 levels in PCa (MartensUzunova et al., 2012) , opposite to the elevated expression of its KLK2 and KLK4 targets (Avgeris et al., 2012) . Among the different variants of miR3783p (miR 378aj and miR422a), miR378a3p (previously annotated as miR378 or miR422b) is the predominantly expressed variant of the miR378/422a family, encoded by MIR378A, an intronic miRNA encoded gene embedded within the first intron of PPARGC1B gene in the 5q32 chromosomal locus.
Although MIR378A has been studied in various human malignancies, its function and expression profile has not been fully elucidated yet. MIR378A overexpres sion in U87 glioblastoma and MT1 breast carcinoma cells was essential for cell survival, tumor growth, and angio genesis, through the downregulation of SuFu and Fus1 tumor suppressors by miR378a5p (Lee et al., 2007) , while miR378a3p was found to be crucial for Mycmediated cell transformation, following the silencing of the TOB2 anti proliferative factor (Feng et al., 2011) . Regarding nonsmall cell lung cancer, mir378a overexpression in NCIH292 cells resulted to downregulation of HMOX1 and increased cell proliferation and migration (Skrzypek et al., 2013) , while higher miR378 levels were associated with patients' brain metastasis, tumor growth, and angiogenesis of A549 xenografts (Chen et al., 2012) .
However, studies of miR378 in the pathophysiology of the heart question its oncogenic properties. In particular, reduced miR378 levels have been found in hypertrophic heart growth and cardiac failure (Ganesan et al., 2013; Nagalingam et al., 2013) . These antihypertrophic activities of miR378 are mainly exerted through the suppression of the MAPK/ERK and PI3K/AKT signaling pathways. More precisely, miR378 overexpression blocks cardiac hyper trophy by preventing Ras activation and thus MAPK/ERK and PI3K/AKT downstream cascades, by targeting the GRB2 upstream mediator (Nagalingam et al., 2013) , as well as MAPK1 (ERK2), IGF1R, and KSR1 members of the MAPK pathway (Ganesan et al., 2013) . The miR378amedi ated regulation of IGF1R signaling is even more critical in PCa pathogenesis. Overexpression of miR378 resulted to the translational inhibition of IGF1R and to apoptotic cell death, while miR378 knockdown launches IGF1Rrelated Akt cascade (Knezevic et al., 2012) . In order to evaluate miR378 clinical significance for PCa, we measured miR378 levels in cancerous and benign prostate tissues. Decreased miR378 levels were found in PCa patients compared to BPH control ones. In PCa patients, miR378 loss was further correlated with high Gleason score, tumors with larger diameter, and elevated serum PSA levels. Motivated by the correlation of miR378 loss with unfavorable prognostic markers, we analyzed the significance of miR378 in the survival outcome of the patients. As expected, Cox regression analysis revealed a significantly higher risk for relapse of the patients with reduced miR378 levels, and KaplanMeier DFS curves indicated the correlation of miR378 loss with the shorter DFS intervals following radical prostatectomy. Interest ingly, miR378 quantification was shown to be able to improve significantly the Gleason score or tumor stage based risk stratification of the patients.
The prognostic significance of miR378 was further evaluated in 'low' and 'intermediate'recurrence risk as well as in 'high' and 'very high'recurrence risk patients. Interestingly, the loss of miR378 in high and very high risk groups of patients ( ≥ pT3a or Gleason score: 8-10 or PSA > 20 μg/l) predicts their shortterm relapse, highlight ing the utility of miR378 for a more accurate prognosis of high and very highrisk group. KaplanMeier curves suggested significantly worse DFS of the patients display ing miR378 loss, while univariate Cox regression analysis pointed out an approximately threefold higher risk for relapse. Multivariate models highlighted that the predic tion of the shortterm relapse of the PCa patients with miR 378a loss and their poor DFS is independent of Gleason score, tumor stage, serum PSA levels, age, and DRE. These results not only support a possible central role of miR378 in disease progression but also underscore miR378 as a novel independent prognostic marker for 'high' and 'very high'recurrence risk cohort.
Although prostate carcinogenesis is not the result of a single molecular event, ligandindependent pathways (outlaw pathways) of AR overactivation, especially in the late disease stages, are essential for disease progres sion and aggressiveness. Regarding 'outlaw' activation of AR, receptortyrosinekinases (RTK) signaling, medi ated mainly by IGF1R, and IL6 and IL8related signaling, triggers AR overactivation through PI3K/AKT, MAPK, and JAK/STAT3 pathways, while KLK2 and KLK4 have been found to enhance AR activity in an androgenindependent manner (Mavridis et al., 2014) . Consequently, the ability of miR378 to target KLK2 and KLK4, along with IGF1R sig naling and key components of MAPK and AKT pathways, highlights a possible regulatory role of miR378 upon AR signaling in prostate cells. This is in agreement with the observed, in our analysis, correlation of miR378 down regulation with higher Gleason score and largerdiameter prostate tumors, as well as with the poor survival expec tancy of the patients.
In conclusion, in the present study, we have identified in silico miR378 as a common regulator of KLK2 and KLK4 PCarelated members of the KLK family and analyzed miR378 clinical significance for the prognosis of PCa patients. Reduction of miR378 levels was observed in PCa tissues compared to benign gland lesions. The downregu lation of miR378 expression was correlated with disease progression, as patients with higher Gleason score tumors and elevated serum PSA concentrations were found to have significantly lower miR378 levels. This was further verified by the higher risk for relapse and the worse DFS of the patients with lower miR378 expression. Finally, in high and very highrecurrence risk patients, miR378 loss was shown to predict the shortterm relapse follow ing treatment of PCa patients independent from Gleason score, tumor stage, PSA levels, and age. Overall, these findings highlight the reduced expression of miR378 in PCa, the correlation of miR378 downregulation with high Gleason score tumors and elevated serum PSA levels, and finally the ability of miR378 to predict the survival outcome of the treated patients, supporting, in this way, miR378 potential use to improve PCa prognosis.
Materials and methods miRNA targeting prediction analysis
MiRanda, TargetScan, DIANA microT v3.0, miRTarget2, MicroCosm, PITA, RNA22, and miRWalk online available programs (see Table 1 for links to the abovementioned algorithms) were used for the pre diction of KLK2-and KLK4targeting miRNAs via miRecords (http:// www.mirecords.umn.edu/miRecords/), miRNA body map (http:// www.mirnabodymap.org/), and miRWalk (http://www.umm.uni heidelberg.de/apps/zmf/mirwalk/) databases. The analyses were performed using the databases' default parameters.
Study population
Prostate tissue specimens were obtained from 73 PCa patients who underwent radical retropubic prostatectomy (Supplemental Tables  2 and 3 ) and 64 transurethral or open prostatectomy treated benign prostate hyperplasia (BPH) patients. Focusing on PCa patients, a tis sue sample of approximately 200 mg was sectioned from the periph eral zone of prostate gland based on the preoperative features of the biopsy and on macroscopic findings. The sample was thereafter divided into two mirrorimage specimens, one of which was tested by a pathologist, while the other one was immediately frozen in liq uid nitrogen and stored at 80°C until analysis. None of the patients included received hormonal therapy or radiotherapy prior to surgery. The last measurement of serum PSA prior to prostate biopsy and diagnosis, approximately 1-2 months prior to radical prostatectomy, was used in our analysis. Our study was approved by the ethics com mittee of 'Laiko General Hospital' and performed with respect to the ethical standards of the Declaration of Helsinki, as revised in 2008.
The followup data from 62 PCa patients were used for the assessment of miR378 prognostic significance for prostate cancer, while 11 PCa patients were excluded from the monitoring plan due to either unclear followup data or the administration of adjuvant therapy before biochemical recurrence. PCa patients' were followed up according to European Association of Urology (EAU) guidelines, and biochemical relapse was defined by two consecutive measure ments of serum PSA ≥ 0.2 μg/l. The National Comprehensive Cancer Network (NCCN) guidelines for PCa (Supplemental Table 1 ) were fol lowed for the evaluation of patients' recurrence risk (Mohler et al., 2010) .
Extraction and polyadenylation of total RNA
Total RNA was isolated using TRIReagent (Molecular Research Center, Inc., Cincinnati, OH, USA) according to manufacturer's instructions, following the pulverization of 60-120 mg of tissue specimen. Total RNA concentration and purity were determined spectrophotometrically at 260 and 280 nm, while RNA integrity was evaluated by agarose gel electrophoresis. Thereafter, 1 μg of total RNA was polyadenylated at the 3′end in a 15μl reaction at 37°C for 60 min using 800 μm ATP and 1 U of Escherichia coli Poly(A) Poly merase (New England Biolabs Inc., Ipswich, MA, USA). Enzyme heat inactivation was performed at 65°C for 15 min.
First-strand cDNA synthesis
The polyadenylated total RNA was reversed transcribed in a 20μl reaction containing 50 U MMLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA), 40 U recombinant ribonuclease inhibitor (Invi trogen), and 0.25 μm poly(T) adapter 5′GCGAGCACAGAATTAATAC GACTCACTATAGGTTTTTTTTTTTTVN3′ (V = G, A, C and N = G, A, T, C) at 37°C for 60 min (Avgeris et al., 2013; Mavridis et al., 2013) . The reverse transcriptase was inactivated by heating at 70°C for 15 min.
Quantitative real-time PCR (qPCR)
Specific forward primers for the miR378a and the small nucleolar RNA, C/D box 48 (SNORD48), also known as RNU48, were designed based on their published sequences (NCBI RefSeq accession number: NR_029870.1 and NR_002745.1, respectively) and in silico specificity evaluation. Moreover, a universal reverse primer, able to hybridize to the abovementioned poly(T) adapter, was also synthesized. The com bination of the 5′GGACTGGACTTGGAGTCAGAA3′ forward primer for miR378a or the 5′TGATGATGACCCCAGGTAACTCT3′ forward primer for SNORD48 with the universal reverse primer 5′GCGAGCACAGAAT TAATACGAC3′, amplified a 67bp miR378 and a 105bp SNORD48 specific amplicon, respectively (Avgeris et al., 2013; Mavridis et al., 2013) .
The qPCR assay was performed in the 7500 RealTime PCR Sys tem (Applied Biosystems, Carlsbad, CA, USA), and the 10μl reaction consists of Kapa SYBR ® Fast Universal 2x qPCR Master Mix (Kapa Bio systems, Inc., Woburn, MA, USA), 200 nm of each PCR primer, and 0.2 ng of cDNA. The thermal protocol comprised of a 3min polymerase activation step at 95°C, 40 cycles of denaturation at 95°C for 15 s, and a primer annealing and extension step at 60°C for 1 min. Following the amplification, melting curve analysis and agarose gel electropho resis were used for the determination of specific reaction products compared to nonspecific ones or primer dimmers. Using serial dilu tions of a control cDNA as template, calibration curves for miR378 and SNORD48 amplification were generated covering six orders of magnitude (Supplemental Figure 3) . The linear increases of miR378 (y = 3.47x+43.49; r 2 = 0.991) and SNORD48 (y = 3.32x+38.02; r 2 = 0.999) amplification highlighted the 94.3% and 99.9% reaction efficiencies, respectively, as well as the absence of PCR inhibition by the template.
Relative quantification (RQ) of miR378 was performed using the 2 ΔΔC T method, where the LNCaP prostate cancer cell line was used as our assay calibrator and SNORD48 as an endogenous reference con trol (Larne et al., 2009 ). Duplicate reactions were performed for each tested sample, and the average C t was calculated for the quantifica tion analysis. No template controls, reverse transcriptasenegative controls, Poly(A) polymerasenegative controls, and DNA template controls generated undetectable C t or > 36.
Statistical analysis
The analysis of miR378 levels between PCa and BPH patients was performed using the MannWhitney Utest. Univariate logistic regres sion analysis, calculating log 10 miR378 odds ratio (OR) and ROC curve analysis were used for the evaluation of miR378 ability to discrimi nate PCa from BPH patients. Differences in miR378 expression levels among patients of different Gleason score, tumor stages, PSA group, or digital rec tal examination (DRE) were analyzed using MannWhitney U and KruskalWallis tests. The correlation of miR378 expression with PCa patients' PSA levels and tumor diameter was assessed by Spear man's correlation coefficient (r s ). Using the Xtile algorithm, the 3.12 RQ units of miR378 (equal to the 52nd percentile of the PCa patients' cohort) were adopted as an optimal cutoff to classify PCa patients into miR378(+) and miR378() cohorts, expressing higher and lower miR378 levels, respectively.
The prognostic significance of miR378 was evaluated by Kaplan Meier survival analysis, using log rank test, and Cox proportional hazards regression models. Univariate and multivariate Cox regres sion models were employed for the calculation of the hazard ratio (HR) of miR378, Gleason score, tumor stage, serum PSA, patient's age, and DRE.
